Ocugen Inc (OCGN)
NASDAQ:OCGN

Ocugen Stock Analysis & Ratings

OCGN Stock Chart & Stats

Day’s Range$2.04 - $2.33
52-Week Range$1.67 - $17.65
Previous Close$2.24
Volume5.24M
Average Volume (3M)10.74M
Market Cap$480.93M
P/E Ratio-6.4
Beta4.62
Next EarningsAug 19, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score1
EPS (TTM)-0.35


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

OCGN FAQ

What was Ocugen’s price range in the past 12 months?
Ocugen lowest stock price was $1.67 and its highest was $17.65 in the past 12 months.
    What is Ocugen’s market cap?
    Ocugen’s market cap is $480.93M.
      What is Ocugen’s price target?
      The average price target for Ocugen is $7.38. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $15.00 ,the lowest forecast is $3.50. The average price target represents 230.94% Increase from the current price of $2.23.
        What do analysts say about Ocugen?
        Ocugen’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Ocugen’s upcoming earnings report date?
          Ocugen’s upcoming earnings report date is Aug 19, 2022 which is in 88 days.
            How were Ocugen’s earnings last quarter?
            Ocugen released its earnings results on May 06, 2022. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of $0.013 by -$0.103.
              Is Ocugen overvalued?
              According to Wall Street analysts Ocugen’s price is currently Undervalued.
                Does Ocugen pay dividends?
                Ocugen does not currently pay dividends.
                What is Ocugen’s EPS estimate?
                Ocugen’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Ocugen have?
                Ocugen has 215,660,000 shares outstanding.
                  What happened to Ocugen’s price movement after its last earnings report?
                  Ocugen reported an EPS of -$0.09 in its last earnings report, missing expectations of $0.013. Following the earnings report the stock price went down -5.263%.
                    Which hedge fund is a major shareholder of Ocugen?
                    Among the largest hedge funds holding Ocugen’s share is Gotham Asset Management LLC. It holds Ocugen’s shares valued at N/A.

                      ---

                      Ocugen Stock Analysis

                      Smart Score
                      1
                      Underperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $7.38
                      ▲(230.94% Upside)
                      Moderate Buy
                      The Ocugen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Ocugen Inc

                      Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Vericel
                      Zimmer Biomet Holdings
                      Surgalign Holdings
                      Anika Therapeutics
                      Globus Medical

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis